Finance News
Complete Finance & Business News Journal

3 Charts Suggest Biotech Stocks Are Headed Higher


Recent events have clearly illustrated the important role that companies within the biotechnology sector have in modern society. Given the volatile nature of biotech, many active traders look to the hitliste of popular exchange-traded products and their top holdings for clues as to the future direction of the segment. In this article, we’ll take a look at several hitliste from across the biotechnik space and try to determine how traders plant be positioning themselves over the weeks and months ahead.

SPDR S&P Biotech ETF (XBI)

As mentioned above, many active traders turn to niche exchange-traded products for clues about the future direction of segments such as biotech. As you can see from the chart of the SPDR S&P Biotech ETF (XBI) shown below, the bulls are mit clear control of the momentum.

Recent price action has daher resulted in a bullish crossover between the 50-day and 200-day moving averages, which will most likely be used to situation the beginning of a dominant long-term uptrend. Depending on risk tolerance, traders will most likely look to place buy orders near one of the illustrated trendlines and protect against a selloff by placing stop-loss orders below $97.19.

Novavax, Inc. (NVAX)

As the hunt for a COVID-19 vaccine continues, one of the companies of specific interest to traders is Novavax, Inc. (NVAX). Taking a look at the chart below, you can see that the stock price has rocketed higher so sehr far in 2020, and the bullish momentum stripper little signs of reversing any time soon.

Many followers of technical analysis will likely be watching to see if the recent pullback will continue to send the stock’s price down toward the support of the ascending trendline. At that level, the risk/reward setup would be more palatable than at current levels just below the 50-day moving average.

Invitae Corporation (NVTA)

Another chart that will be of specific interest to active traders is Invitae Corporation (NVTA). As one of the top holdings of the IBB ETF, Invitae will likely be used as a leading indicator for how other mid-cap biotech stocks may perform over the weeks ahead. Taking a look at the chart below, you can see that the price recently rose above the key resistance of a horizontal trendline near $27.50.

The breakout and bounce from the 50-day moving average after a schreiben pullback are clear technical signs that the bulls are in control of the momentum. From a risk-management perspective, traders plant look to buy as close to current levels as possible. To protect against a change mit sentiment or fundamentals, most traders will likely look place stop-loss orders below the trendline or the 200-day moving average, depending on risk tolerance and investment horizon.

The Bottom Line

The important role of biotech companies mit society and investment portfolios has become clear mit recent months. Active traders who follow the hitliste will likely be adding more biotech companies to their portfolios over the months ahead. Based on the proximity to major support levels, it is clear that the risk/reward will remain in the favor of the bulls until prices close below the support levels or technical indicators suggest otherwise. 

At the time of writing, Casey Murphy did mangel own a position mit any of the assets mentioned.

Get real time updates directly on you device, subscribe now.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Translate »